Tech Company Financing Transactions

Adaptive Biotechnologies Funding Round

Adaptive Biotechnologies secured a $195 million financing round on 5/6/2015. Investors included Matrix Capital Management, Alexandria Venture Investments and Casdin Capital.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Proceeds Purpose
This investment will fuel significant expansion of the Company's research platform, support the commercialization of a novel target identification technology for T-cell therapy, and expedite global regulatory submissions and launch timelines for its research-use-only and clinical diagnostic products. Additionally, funds will be allocated to support the continued growth of the world's largest database of adaptive immune receptors to inform future diagnostic and therapeutic discoveries across disease states.

Company Information

Company Status
Mailing Address
1551 Eastlake Ave. East 200
Seattle, WA 98102
Email Address
Adaptive (Nasdaq: ADPT) is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
Adaptive Biotechnologies LinkedIn Company Profile
Social Media
Adaptive Biotechnologies Company Twitter Account
Company News
Adaptive Biotechnologies News
Adaptive Biotechnologies on Facebook
Adaptive Biotechnologies on YouTube

Management Team

Email & Social
Chief Executive Officer
Chad Robins
  Chad Robins LinkedIn Profile  Chad Robins Twitter Account  Chad Robins News  Chad Robins on Facebook
Chief Financial Officer
Chad Cohen
  Chad Cohen LinkedIn Profile  Chad Cohen Twitter Account  Chad Cohen News  Chad Cohen on Facebook
Chief Technical Officer
Sean Nolan
  Sean Nolan LinkedIn Profile  Sean Nolan Twitter Account  Sean Nolan News  Sean Nolan on Facebook
Harlan Robins
  Harlan Robins LinkedIn Profile  Harlan Robins Twitter Account  Harlan Robins News  Harlan Robins on Facebook
Christopher Carlson
  Christopher Carlson LinkedIn Profile  Christopher Carlson Twitter Account  Christopher Carlson News  Christopher Carlson on Facebook
VP - Bus. Development
Julie Rubinstein
  Julie Rubinstein LinkedIn Profile  Julie Rubinstein Twitter Account  Julie Rubinstein News  Julie Rubinstein on Facebook
VP - General Counsel
Gene DeFelice
  Gene DeFelice LinkedIn Profile  Gene DeFelice Twitter Account  Gene DeFelice News  Gene DeFelice on Facebook
VP - Operations
Nancy Hill
  Nancy Hill LinkedIn Profile  Nancy Hill Twitter Account  Nancy Hill News  Nancy Hill on Facebook
VP - Regulatory Affairs
Melina Cimler
  Melina Cimler LinkedIn Profile  Melina Cimler Twitter Account  Melina Cimler News  Melina Cimler on Facebook



Browse more venture capital transactions:

Prev: 5/6/2015: Moximed venture capital transaction
Next: 5/6/2015: DrFirst venture capital transaction


Share this article


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary